A large study suggests that pediatric cancer patients are more likely to die in the hospital than at home. The data showed that 52% of patients died in the hospital, and 40% died at home. These ...
The FDA has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone for transplant-ineligible, newly diagnosed multiple myeloma.
The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...
The FDA has approved Rybrevant (amivantamab) in combination with chemotherapy to treat advanced, EGFR-mutant NSCLC that progressed on or after treatment with an EGFR TKI.
(HealthDay News) — Among cancer survivors, excess body weight is associated with an increased risk of a second primary cancer, according to a study published in JAMA Network Open.